← Mechanisms of action
CA9
SINGLE PROTEINHomo sapiens
Preferred name: Carbonic anhydrase IX ChEMBL ↗
Linked proteins
Drugs acting on this target (20)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| ga-oncocaix | Binding agent | experimental | Peptide | CA9 binding agent |
| 111in-dota-cg250 | Immunity, passive | experimental | mAb | CA9 immunity, passive |
| 177lu-dota-cg250 | Immunity, passive | experimental | mAb | CA9 immunity, passive |
| ab-2100 | Immunity, passive | experimental | Cell therapy | CA9 immunity, passive |
| bay79-4620 | Immunity, passive | experimental | mAb | CA9 immunity, passive |
| caix car-t cell | Immunity, passive | experimental | Cell therapy | CA9 immunity, passive |
| cg250 (124i) | Immunity, passive | experimental | mAb | CA9 immunity, passive |
| girentuximab | Immunity, passive | experimental | mAb | CA9 immunity, passive |
| y90 conjugated chimeric g250 | Immunity, passive | experimental | mAb | CA9 immunity, passive |
| 68ga-c1 | Inhibitor | experimental | mAb | CA9 inhibitor |
| ca9hu-1 | Inhibitor | experimental | mAb | CA9 inhibitor |
| dtp348 | Inhibitor | experimental | Small molecule | CA9 inhibitor |
| in111-dota-girentuximab-irdye800cw | Inhibitor | experimental | mAb | CA9 inhibitor |
| slc-0111 | Inhibitor | experimental | Small molecule | CA9 inhibitor |
| girentuximab | Other | experimental | mAb | CA9 other |
| [68ga]ga-dota-caix | Radiopharmaceutical | experimental | Peptide | CA9 radiopharmaceutical |
| [89zr]zr-girentuximab | Radiopharmaceutical | experimental | mAb | CA9 radiopharmaceutical |
| 111in-xyimsr-01 | Radiopharmaceutical | experimental | Recombinant protein | CA9 radiopharmaceutical |
| 68ga-nym005 | Radiopharmaceutical | experimental | Peptide | CA9 radiopharmaceutical |
| 68ga-xt771 | Radiopharmaceutical | experimental | Peptide | CA9 radiopharmaceutical |